Correction: Prognostic factors in patients with heart failure and sarcopenia: an observational retrospective study

• Published in: The Egyptian heart journal Vol. 76; no. 1; pp. 87 - 3
• Main Authors: Imamura, Yasutaka, Suzuki, Atsushi, Kamishima, Kazuho, Suzuki, Kazuhito, Yamaguchi, Junichi
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 08.07.2024; Springer; Springer Nature B.V; SpringerOpen
• Subjects: Cardiac patients; Cardiology; Care and treatment; Correction; Heart failure; Medicine; Medicine & Public Health; Japan
• ISSN: 2090-911X; 1110-2608; 2090-911X
• DOI: 10.1186/s43044-024-00521-2

Text after correction: A comparison of the characteristics of patients with HFpEF and those with HFrEF did not show significant differences in age or body mass index. Causes of death among HFrEF and HFpEF patients All patients (n = 256) HFrEF (n = 83) HFpEF (n = 173) p-value All-cause death 47 (18%) 22 (27%) 25 (14%) 0.020 Cardiovascular or cerebrovascular cause 24 (51%) 13 (59%) 11 (44%) 0.471 Heart failure 18 (38%) 10 (45%) 8 (32%) Ventricular arrhythmia or sudden death 3 (6%) 2 (9%) 1 (4%) Myocarditis 1 (2%) 1 (5%) 0 (0%) Aortic dissection 1 (2%) 0 (0%) 1 (4%) Stroke 1 (2%) 0 (0%) 1 (4%) Other cause 23 (49%) 9 (41%) 14 (56%) Infection 11 (23%) 5 (23%) 6 (24%) Malignancy 5 (10%) 2 (9%) 3 (12%) other non-cardiac cause 3 (6%) 1 (5%) 2 (8%) Unknown 4 (9%) 1 (5%) 3 (12%) Table3 “eGFR per 10 mL/min/1.73 cm2 decrease” needs to be changed to “eGFR per 10 mL/min/1.73 m2 decrease”. Univariate and multivariate analyses related to prognosis Univariate analysis Multivariate analysis HR 95% CI p HR 95% CI p-value Male sex 0.944 0.532–1.673 0.843 Age ≥ 85 years 2.316 1.270–4.227 0.006 2.435 1.3104.526 0.005 NYHA functional class 1.543 1.061–2.244 0.023 1.635 1.100–2.429 0.015 Ischemic etiology 1.318 0.738–2.354 0.350 HFrEF vs.